Avanir Pharmaceuticals Inc (AVNR) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Avanir Pharmaceuticals Inc (AVNR) announced its quarterly results on Monday. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters consensus estimate of ($0.14) by $0.02. During the same quarter in 2010, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 40.00% on a year-over-year basis.

On a related note, analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Avanir Pharmaceuticals Inc in a research note to investors on Thursday, April 28th.

Shares of Avanir Pharmaceuticals Inc (AVNR) opened at 3.98 on Tuesday. Avanir Pharmaceuticals Inc (AVNR) has a 52 week low of $1.31 and a 52 week high of $5.80. The stock’s 50-day moving average is $3.98 and its 200-day moving average is $4.02. The company has a market cap of $483.9 million.

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).